• Purmorphamine Workflows for Hedgehog Research

  2026-08-15

  Use Purmorphamine as a receptor-proximal Smoothened agonist to connect Hedgehog signaling with osteoblast differentiation, mesenchymal stem cell assays, and sensory biology. This practical guide combines dose planning, cross-species assay design, and troubleshooting for more reproducible pathway modulation.

• NMDA: From Excitotoxicity to Ferroptosis Assays

  2026-08-14

  NMDA (N-Methyl-D-aspartic acid) provides a receptor-specific way to investigate excitotoxic injury, calcium signaling, and oxidative damage. This guide connects NMDA model design with ferroptosis-focused readouts from a retinal glaucoma study, helping researchers choose more informative assays.

• NU7441 (KU-57788) in DNA Repair Research

  2026-08-14

  NU7441 (KU-57788) is a potent, selective DNA-PK probe for studying double-strand break repair, cell-cycle responses, and cancer-cell sensitization. This guide connects practical dosing and assay design with emerging PRKDC–PD-L1 biology while separating established evidence from translational hypotheses.

• APOC1 and Cyclopamine in Papillary Thyroid Carcinoma

  2026-08-13

  A 2026 Translational Oncology study identifies APOC1 as a pro-tumorigenic and immune-evasion-associated factor in papillary thyroid carcinoma and uses Connectivity Map analysis to nominate cyclopamine as a candidate treatment. The work further shows that APOC1 depletion sensitizes PTC cells to cyclopamine, providing a mechanistic rationale for combined target validation and pharmacological intervention.

• Niclosamide Workflows for STAT3 Cancer Research

  2026-08-13

  Niclosamide enables a structured evaluation of STAT3-linked growth inhibition, apoptosis, and cell-cycle effects across cancer models. This workflow separates reduced viability from true cell killing, helping researchers interpret responses more rigorously and troubleshoot solubility, timing, and pathway-readout issues.

• Anti Reverse Cap Analog for Reliable mRNA Assays

  2026-08-12

  Learn how Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G (SKU B8175) can improve synthetic mRNA translation workflows that support cell viability, proliferation, cytotoxicity, and reprogramming studies. This scenario-based guide connects cap orientation, in vitro transcription parameters, assay controls, and evidence-based product selection.

• PDGF-BB Workflow for Pulmonary Hypertension Research

  2026-08-12

  Build reproducible vascular-remodeling assays with murine recombinant PDGF-BB as a defined mitogenic stimulus, then connect proliferation readouts to hypoxia-associated metabolic remodeling. This workflow combines dose-response design, receptor-aware controls, and mitochondrial phenotyping for stronger pulmonary hypertension experiments.

• Shh–Fgf Control of Urethral Groove Development

  2026-08-11

  A 2025 Cells study identifies differential Shh, Fgf10, and Fgfr2 expression as a developmental explanation for why guinea pigs form an open urethral groove whereas mice form a tubular urethra without an equivalent groove. By combining comparative gene-expression analysis with genital-tubercle organ culture and pathway perturbation, the work links signaling intensity to species-specific preputial and urethral morphogenesis.

• ABT-888 (Veliparib) Workflow for DNA Repair Studies

  2026-08-11

  ABT-888 (Veliparib) combines strong PARP1/2 target engagement with practical utility in chemotherapy, radiation, and DNA damage response workflows. This guide translates colorectal cancer and MSI model evidence into reproducible assay design while showing why recent leukemia screening data argue for biomarker-aware combination testing.

• Radioiodinated Balsalazide for UC Imaging in Mice

  2026-08-10

  Sanad and colleagues developed and evaluated radioiodinated balsalazide as a colon-targeted tracer for ulcerative colitis in mice. The optimized labeling workflow produced a stable radiotracer with strong uptake in ulcerated colon, supporting preclinical imaging and biodistribution studies while leaving important questions about receptor specificity and clinical translation unresolved.

• BRD4–RAC1 Co-Targeting in Breast Cancer

  2026-08-09

  The reference study shows that simultaneous inhibition of BRD4 and RAC1 suppresses growth, stemness, migration, and tumorigenesis across luminal-A, HER2-positive, and triple-negative breast cancer models. Its mechanistic contribution is the identification of a c-MYC–G9a–FTH1 pathway and HDAC1-associated chromatin response that connect dual pathway inhibition to autophagy, senescence, and reduced tumor growth.

• SLC2A5 Fructose Metabolism in Primary CNS Lymphoma

  2026-08-08

  This Advanced Science study uses single-cell RNA and B-cell receptor profiling to identify SLC2A5-mediated fructose utilization as a metabolic adaptation in primary central nervous system lymphoma. The findings connect glucose-poor, hypoxic tumor microenvironments with lymphoma growth, macrophage support, and T-cell dysfunction, while functional experiments nominate SLC2A5 as a potential therapeutic vulnerability.

• LXR Signaling and Alveolar Cell Survival in BPD

  2026-08-07

  Ma et al. identify disrupted cholesterol homeostasis and reduced LXR signaling as a mechanistic link between hyperoxia and alveolar epithelial cell apoptosis in bronchopulmonary dysplasia. Using preterm infant samples, neonatal rats, and MLE12 cells, the study shows that LXR activation is associated with reduced cholesterol accumulation, oxidative stress, mitochondrial dysfunction, and epithelial injury.

• Cyclopamine in Translational Oncology: Beyond Pathway Inhibi

  2026-08-07

  Explore how Cyclopamine, a potent Hedgehog signaling inhibitor, is reshaping translational cancer research by enabling mechanistic dissection, advanced apoptosis studies, and protocol refinement. This article uniquely connects molecular insights with modern assay design.

• AG-490 (Tyrphostin B42): JAK2/EGFR Inhibition in Cancer Rese

  2026-08-06

  AG-490 (Tyrphostin B42) is a selective JAK2 and EGFR inhibitor with nanomolar to micromolar potency. It modulates the JAK-STAT and MAPK pathways, supporting cancer and immunopathological research. The compound is insoluble in water but offers robust signaling pathway inhibition, enabling dissection of tumor microenvironment mechanisms.

16440 records 1/1096 page Next 12345 下5页 Last page